In discussing the management of the acute patient I will be referring only to the spectrum of psychotic disorders characterized by rapid onset (over days or weeks) of disturbances in thought, affect and perception in adults. This encompasses a variety of clinical conditions from acute schizophrenia to mania, and to organic causes of delirium.
The acute psychotic episode represents a medical emergency for several reasons. First, the acutely psychotic individual is frequently in danger of impulsive self-mutilation, suicide or homicide. Second, the psychosis is usually an intensely painful state. In addition, some suspect that delayed treatment may contribute to incomplete remission of symptoms (Anderson & Kuehnle 1974) . Until recently, the acute psychosis was managed by protective custodial care and non-neuroleptic medication. A discussion on the efficient management of the acute patient has only been possible in the last twenty years, since the introduction of the major tranquillizers.
The efficient management of the acute patient involves several immediate decisions, based on a thorough history, mental status, physical examination and collateral history, including answers to the questions: (I) Is any psychiatric treatment indicated? (2) Is hospitalization indicated? (3) Should the patient be admitted informally or involuntarily? (4) Is the patient competent to manage his affairs? (5) What is the provisional diagnosis ?
In general, hospitalization is necessary when: (1) Patients are homicidal or suicidal as a result of the psychotic process. (2) Patients lack adequate family and community support. (3) The psychotic process does not remit sufficiently within a short period of adequate treatment. (4) A delirium is present.
Hospital gives the opportunity both to search for etiological factors and for intensive nursing care.
Following these immediate decisions, aggressive treatment of the psychotic process must begin with one of the neuroleptic medications. The issue here is: which drug and how much should be used? Choice of an antipsychotic agent should be based on a number of factors. These include: the patient's past history of response; the doctor's familiarity with the drug; sedating effect; untoward effects; route of administration and dosage; potency and cost. The Patient's Past History ofResponse In general, if a patient has not responded to one specific drug or has had a toxic response to that drug, it is best not to use it for subsequent psychotic episodes. Conversely, if a rapid remission was previously obtained, one may suspect that future episodes will also respond to the medication.
The Doctor's Familiarity with the Drug There are about 20 major tranquillizers currently marketed for the treatment of psychosis. No physician can expect to become knowledgeable in the use of all of them. It is best to select several that one can use responsibly, with full knowledge of their pharmacologic properties. In other words, use a few drugs well, rather than all drugs poorly.
Sedating Effect
In general, the more sedating phenothiazines are the less potent neuroleptics. It is often assumed that a high-sedative effect is essential in the management of the acute psychosis. Recently, Man & Chen (1973) and Sangiovanni et al. (1973) have found this to be false. The high potency, less sedating antipsychotics are quite effective in managing even the very excited patient. In addition, the acute psychotic may be more comfortable if less obtunded.
Untoward Effects
In the acute phase of rapid tranquillization, the limiting factor in drug administration is likely to be the development of hypotension. Haloperidol and the high potency piperazines show far less tendency to produce hypotension in equivalent antipsychotic dosages. In using haloperidol intramuscularly every six to eight hours, Ritter et al. (1972) observed no hypotension. Sangiovanni et al. (1973) had one hypotensive episode in 18 haloperidol-treated patients. Sainsbury (1969) gave up to 90 mg haloperidol parenterally daily for delirium tremens without the development of hypotension. Similarly, Oldham & Bott (1971) reported that 11 % of their haloperidoltreated patients had a fall in systolic blood pressure of more than 20 mmHg. But only 4% had a fall to less than 100 mmHg. Man & Chen (1973) found two of 15 chlorpromazine-treated patients but no haloperidol-treated patients developed hypotension. These reports of high dosage, high potency drugs producing little hypotensive effect are a distinct improvement in the rapid tranquillization of the acutely psychotic. There is also some evidence that the high potency neuroleptics give lower incidence of other toxic effects, including hepatic, hmmopoietic, cardiovascular and eye changes than do the low potency drugs (Gerle 1964 , Shader & DiMascio 1970 .
One of the major concerns relating to the use of haloperidol is the frequency of extrapyramidal side-effects (EPS). With regard to this I would like to mention two things. The first is their relation to dose. In 1967 Crane reviewed the existing literature and concluded that these EPS were dose related. He also noted that there is little increase in side-effects in the dose range of 16 to 32 mg haloperidol daily. Since then there have been reports by Rifkin et al. (1971) and Sangiovanni et al. (1973) that with high dosage neuroleptics, the EPS may actually be less frequent than at low doses. The exact relationship between EPS and dose of haloperidol therefore merits further evaluation.
The second factor relating to the EPS concerns their treatment. As you know, benztropin mesylate or other anti-parkinsonian agents are very useful for this. These agents should not be used routinely, but rather only when EPS develop. One important fact, often overlooked, is that continued treatment with benztropin is usually not necessary. As Orlov et al. (1971) and McClelland et al. (1974) have shown, discontinuation of the anti-parkinsonian agent after three months is associated with recurrence of symptoms in less than 10 % of patients.
Roite ofAdminiistration and Dosage
For the acutely agitated psychotic patient, intramuscular administration is best at the start. If this is not feasible, then oral liquid concentrate is preferable to tablets which may be easily disposed of. When using intramuscular medication, one factor to consider is the degree of pain caused at the injection site, particularly when multiple injections are to be given. In this instance, high potency compact drugs such as haloperidol are preferable to drugs such as chlorpromazine which require a large volume of solution.
Turning to dosage, Forsman & Ohman (1974) have demonstrated up to tenfold differences in serum concentration in patients on a standard dose of haloperidol, thus indicating large individual differences in absorption or metabolism of the drug. Therefore, dosage must be individually titrated for each patient. With haloperidol the initial dose should be either 5 or 10 mg intramuscularly depending on age, weight, severity of illness and previous response to other neuroleptics. The frequency of subsequent injections is determined on the basis of therapeutic response or the development of adverse side-effects.
In determining the frequency of parenteral medication, caution has prevailed. The 1973 edition of Conn's 'Current Therapy' suggests administration three times a day, with a transfer to oral medication in two or three days (Malitz 1973) . Recent studies using haloperidol suggest that control of the patient's behaviour can be obtained in a matter of hours, rather than days. Peak blood levels occur in 10 minutes and clinically significant physiological effects are observed within 30 to 45 minutes after intramuscular injection of haloperidol.
Palestine (1973) administered haloperidol parenterally at 60-minute intervals and controlled the severe agitation in patients with alcoholic withdrawal within three hours. Reschke (1974) found that over 80% of acute schizophrenic episodes could be behaviourally improved within two hours by administering haloperidol every 30 minutes. Similarly, Man & Chen (1973) have described a rapid tranquillization technique using 5 mg of intramuscular haloperidol every 30 minutes, and found it useful in reducing the symptoms of agitation, hostility and aggression in an average time of 2.5 hours. In brief, while control of the initial phase of the psychosis may take several days using haloperidol every six to eight hours (Feldman et al. 1969 , Sangiovanni et al. 1973 ), parenteral administration hourly may allow for behavioural control in a matter of hours. The advantage of this is obvious: a total treatment regimen can begin sooner.
The total dose necessary for the stabilization of the acute patient varies widely. Optimal results are obtained with 40-60 mg haloperidol for most patients. However, about 20 % may require considerably more than this (Sangiovanni et al. 1973) . During this stabilization phase, the patient should be recumbent, in a quiet room and accompanied by a staff member.
Following the initial control of the acute psychotic patient, several factors become important. The first of these is the switchover to oral medication. The timing of this conversion must be individualized for each patient depending on behavioural control. With hourly parenteral haloperidol most patients can be an oral medication within four to eight hours. Use of a less aggressive parenteral approach may require longer periods. Sangiovanni et al. (1973) , using 10-30 mg haloperidol up to three times daily, found that excitement could be controlled in 60 % of patients by 24 hours and in 90 % by 72 hours. The dose of oral medication necessary for each individual is again variable. As a rough guide, patients will usually require about twice the parenteral dose that was necessary for behavioural control as a daily oral dose to control the psychosis initially. For example, if a patient required 10 mg hourly for four hours for behavioural control, a reasonable oral dose would be 80 mg haloperidol per day.
Since the half-life of haloperidol has been shown to vary between 12 and 22 hours, administration twice a day would be adequate (Forsman & Ohman 1974) . Again this dosage would be varied according to therapeutic results or the appearance of side-effects. While initial behavioural control occurs in a matter of hours, remission of the primary psychotic symptoms is gradual and takes weeks (Lehmann 1969) .
In addition to pharmacotherapy, the time of inpatient treatment can be utilized in an effort to rebuild contacts with family and the community. Attention should be given not only to achieving remission of psychosis but to improving the patient's socially adaptive resources. An effective social service department and rehabilitation team is of great value here.
The time for discharge from hospital occurs when the original indications for admission have subsided and when strengths within the patient, family and community have been utilized to ensure maximal rehabilitation and the assurance that outpatient follow up will be continued.
Following Maintenance pharmacotherapy has been shown to be useful in the treatment of schizophrenia. If therapy is interrupted the risk of a relapse is between 30 % and 50% (Prien & Klett 1972) . The duration will vary depending on the number of relapses the individual has had. For the first psychotic episode, Lehmann (1969) has suggested six months maintenance; after the second episode 12-18 months; after three or more acute psychoses, consideration should be given to lifelong maintenance therapy.
It is during the maintenance phase that two other considerations about choice of neuroleptic assume importance: potency and cost. As Hollister (1970) has noted, 'harmful effects of drugs or chemicals in the environment are not appreciated for decades after their introduction, it seems prudent to reduce the total body burden as much as possible ... We simply do not know whether it is preferable to give 20 mg daily of a foreign molecule rather than 200 mg'. Use of high-potency, low-dose drugs or alternatively low-potency drugs with drug holidays are in order.
Similarly, with other factors being equal, consideration should be given to using a major tranquillizer that will be least expensive to the patient over a long period of use.
Supportive psychotherapy should coincide with maintenance pharmacotherapy. Here the aims should include encouraging continued use of the neuroleptic; recognition of early signs of relapse and repair of the disturbed social relationships that occur with major psychotic symptoms. It is only when psychotherapies and pharmacotherapies coincide that we can hope to decrease the frequent drop-outs from treatment and subsequent high rate of relapse. 
DISCUSSION
Dr F J Ayd (Maryland) asked whether Dr Oldham had found prophylactic use of anti-parkinsonian drugs to be of value and had continued to use it, or whether he now only gave anti-parkinsonian medication when patients had extrapyramidal reactions.
Dr Oldham agreed with the earlier conclusions of Dr Ayd and Dr Kristjansen that for long-term therapy an anti-parkinsonian drug should not be prescribed until parkinsonian side-effects occurred and then they should be carefully monitored and discontinued progressively on a trial basis.
His own observations related to acute treatment, lasting a few days. There were two problems. The first was acute dystonia which could be very distressing to the patient and which had motivated some to refuse further treatment. The second consideration was the availability of doctor time. For these two reasons an automatic regime involving a short period of anti-parkinsonian therapy had been routinely adopted by Dr Bott and himself.
Further answering Dr Ayd he said that he had analysed dystonic reactions with respect to age and sex. The most distressing cases were in the older age groups. However, he had only seen 5 cases of parkinsonism which had not been resolved following discontinuation of anti-parkinsonian drugs, haloperidol and other major tranquillizers. In the younger age groups, parkinsonian symptoms had disappeared when drugs had been discontinued.
Dr F J Ayd (Maryland) asked whether acute dystonic reactions had occurred more frequently with intramuscular medication than would be expected in patients given oral medication.
Dr Oldham said that in his study, anti-parkinsonian medication had been given routinely and the decision was based on previous clinical experience. They had not therefore quantitatively studied this question.
Dr G F Westcott (Brentwood) described his experience with 2 mg intramuscular injections every hour, so that in one day patients received up to 240 mg. He sometimes found it necessary to give 150 to 240 mg a day perhaps for 3 consecutive days, which involved a large number of needle punctures. However, the drug could be given in any portion of the body and in his experience most patients could be normalized with these high doses in 1-2 days.
The disappointment had been that on switching to oral medication, the same dose of concentrate did not have the same effect. After 200 mg i.m., four doses of 50 mg of the concentrate might allow complete relapse into a psychotic state, in which case it had been necessary to switch to trifluoperazine (50 mg twice daily) to maintain control.
Dr A J Coppen (Chairman) asked for discussion of the difference between oral and parenteral administration.
Dr Garfinkel said that he too had used intramuscular medication hourly to control the psychotic process. Usually 80-100 mg was sufficient although 140 to 150 mg might be required. It seemed a mistake to convert mg for mg from intramuscular to oral administration. A ratio of 2:1 was probably more accurate. For example, a patient given 60 mg over 6 hours i.m. should probably be given another 20-30 mg later in the day orally and subsequently receive twice the dose of that originally given, rather than switching to another drug.
Dr G F Westcott (Brentwood) asked if there was any correlation between this phenomenon and any local anesthetic effect of the high dosage concentrate, as found, for example, with trifluoperazine. The latter in high concentration produced insensitivity of the patient's palate. He enquired about the rate of absorption of haloperidol concentrate from the gut.
Dr A J Coppen asked Dr Oldham if he had comments on the difference between oral and parenteral administration.
Dr Oldham said that his work referred largely to the control of acute excitement. On admission, the control of excitement was paramount. He had heard of hourly injections but not personally tried them. He would avoid anything that disturbed the patient's cooperation.
In reply to the Chairman's further questioning he said that he would give haloperidol intramuscularly even to a patient who was prepared to swallow it. This was because in his experience it worked much better when given intramuscularly than by mouth. Dr A J Coppen asked Dr Forsman to comment on this observation that the drug is more effective parenterally than orally. Dr A 0 Forsman (Gothenburg) said that the bioavailability of haloperidol was around 60 % which agreed well with the suggestion that the oral dose must be twice that given parenterally.
On the local anesthetic effect, he had also studied thioridazine which had peripheral anticholinergic effects that did indeed diminish its absorption. He had seen no such effect with haloperidol nor did he anticipate one since the anticholinergic effect of haloperidol, if indeed it existed, was central and not peripheral.
Professor W Keup (Berlin) asked whether those patients who developed parkinsonian side-effects were excluded from the higher dosages, thus giving a somewhat artificial situation. He had used haloperidol precisely because of its high frequency of parkinsonian side-effects to counteract choreic movements.
Dr Garfinkel said that in many studies, for instance that of Sangiovanni and of Oldham, initial doses were in the order of 30 mg three times a day intramuscularly, so that many patients were on very high doses from the start. He thought failure to elicit parkinsonian reactions was a real phenomenon although its cause was unknown. The anticholinergic effect was a possibility but no-one seemed to hold the complete explanation.
Dr H S Karunasekara (Devizes) questioned the safety of giving haloperidol intravenously. Recently a restless, disturbed and difficult 50-year old woman had been admitted. With a diagnosis of mania she was given 20 mg haloperidol intravenously. She went into a state of collapse within 15 minutes and died within an hour. The post-mortem cause of death was given as coronary thrombosis. He therefore questioned the value of giving the drug by this route.
Dr Oldham said that one of the reasons for adopting the intramuscular technique in acutely excited patients was the difficulty of giving intravenous injection. The acute manic patient could be given intravenous drugs and he had done so with the haloperidol; none the less it might necessitate techniques of restraint which were inimical to peaceful treatment. In his experience the intramuscular technique very frequently produced tranquillization within 30 minutes. Therefore he had long since abandoned the intravenous method, which had proved unnecessary, quite apart from any danger inherent in it.
Dr G F Westcott (Brentwood) said that the nonappearance of extrapyramidal symptoms correlated with-the rapidity with which the patient was titrated. The antipsychotic effect and the extrapyramidal effect seemed to be related to the dopamine-binding ability and adrenergic binding ability of the drug. He considered it possible that with rapid titration, the dopamine-binding effect (which is basically the antipsychotic effect) could appear much more quickly than the adrenergic binding effect. A hypothesis of substrate competition in the basal ganglia preventing extrapyramidal effects might be tenable. It was certainly true that 200 mg could be given daily with no extrapyramidal effects at all; but if the level was decreased to 20 mg daily anti-parkinsonian drugs might become necessary. Dr J S Howard (Fresno) asked whether, when a patient deveioped extrapyramidal side-effects on low doses it would be proper, because of the theoretical considerations that had been given, to increase the patient's dosage, expecting the extrapyramidal effects to disappear.
Dr Garfinkel said that one could not predict for any individual patient whether the effects would disappear. In practical terms, effective means existed for treating extrapyramidal symptoms when they did occur but it would certainly be interesting to see how regularly they disappeared on increasing the dosage.
Dr A M van Leeuwen (Amersfoort) said that extrapyramidal symptoms could be lessened by anti-parkinsonian agents. But he had seldom seen them disappear completely.
Dr Garfinkel said that there were times when they were controlled and there were many occasions when they did disappear. In his experience it was very infrequent to have to stop the medication because of the extrapyramidal symptoms.
Dr Oldham said in his study of 4 cases of extrapyramidal symptoms, 3 were treated by continuing anti-parkinsonian drugs and actually lowering the dose to below 20 mg. He now tended to raise the dosage very rapidly to over 60 mg, but anti-parkinsonian drugs were of course given routinely.
Dr Garfinkel said that patients who had been on chlorpromazine and were now on haloperidol really appreciated the transfer, and they had said so. This was because of the lessened degree of obtundedness and also because some of them had had hypotensive effects in the past. They therefore preferred haloperidol.
Dr Oldham considered this a most important point. The patient's reaction might not only make him stop treatment; patients who suffered told other patients and relatives, producing an adverse clinical effect. For intensive treatment Dr Oldham liked the patient to have a single injection, to be tranquillized within half an hour in a single room in bed, and to be quiet and tranquillized until the next injection. In his view, acute dystonia was the most distressing symptom which patients had and if this could be avoided cooperation with subsequent treatment was generally very good. Dr S V Nirgude (Darlington) suggested that patients on haloperidol without anti-parkinsonian drugs responded better to the rarely experienced side-effects of the drug than those put routinely on anti-parkinsonian medication. He wondered whether these side-effects were responsible for the better results or whether anti-parkinsonian medication reduced the efficacy of the drug. Dr Garfinkel said that several years ago people felt that these side-effects were necessary for improvement of the psychotic process. There was no evidence to suggest so now, and no reason to suggest increasing the dose until side-effects appeared. They were in no way beneficial in treating the psychotic process.
Dr R K Brahma (London) inquired about the dosage used in the over-50 and over-60 age groups who might be equally restless and in almost acute confusional state through psychotic restlessness.
Dr Oldham said that he had ceased to use highdosage haloperidol for the over-60s and over-65s. In general this was done for physical considerations, but in particular because of the small number of cases of irreversible parkinsonism which he had seen over the years.
Dr R K Brahma (London) asked how one could relate this finding to the theoretical explanation that high doses of haloperidol reduced the extra-pyramidal side-effects by increasing anticholinergic effects.
Dr A J Coppen suggested that this topic might be brought up in a later discussion.
Dr C de B White (London) said that the central anticholinergic potencies of various neuroleptic agents had now been published in the British Journal of Pharmacology and in Nature. Tables now existed showing the relative potency of anticholinergic properties of the drugs compared with their dopamine-blocking properties. There was no doubt that haloperidol did have some anticholinergic activity. It was striking that the most potent anticholinergic drug of the series was thioridazine which was noted not to have parkinsonian side-effects or dystonic side-effects to the same extent as other neuroleptic agents. In his own clinical experience Dr White had found dystonia to be a serious problem in some cases, which anticholinergic agents did not always help.
He wondered if anybody had done a trial with thioridazine comparable to that with haloperidol or tried thioridazine as a drug for acute management.
Dr Garfinkel said that the difficulty with thioridazine was the marked limitation to a certain dose level. The individual dosage was not obvious for any patient; it must be titrated. There was evidence that going over 800 mg a day of thioridazine caused danger of retinal pigmentation. Thioridazine had potency equal to chlorpromazine so that the acute manic patient could often be expected to reach this dose range. It was a real problem to have to transfer him after 6 hours because of this.
Dr J C Maerz (Fort Washington) said that thioridazine was not available as an injection and so it could not be used for rapid tranquillization. In addition, sedation might be excessive and partial hypotension might be found. They were currently using it for oral tranquillization, 20-40 mg hourly and these studies would soon be published. They used the system of adequate individualized doses in the aged. The initial dosage was not so important a consideration as how fast and how safely more drug could be given. Titration was by response, and not from data in the literature. The rate of titration should be slow. Manic depressive aged patients in particular might need higher doses but this could not be predicted. The procedure was to start at a low dose and monitor patients closely.
